Parth Rali, MD
Pulmonary Disease · Philadelphia, PANPI 1326398421
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (45.6%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Inari Medical, Inc. at 54.3% of the total. Among pulmonary disease clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 319 payments — averaging $983.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inari Medical, Inc.$171K
- Stryker$40K
- Johnson & Johnson$35K
- Viz.ai, Inc.$14K
- Merck$13K
- United Therapeutics Corporation$10K
- plus $31K from 15 others
Across 206 payments — averaging $2427.87 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- United Therapeutics Corporation$309K
- Inari Medical, Inc.$79K
- Penumbra, Inc.$38K
- Daiichi Sankyo Inc.$31K
- Boston Scientific$20K
- Endovascular Engineering Inc.$16K
- plus $8K from 1 others
What the payments were for
- Consulting fees$110,65535%
- Speaking & faculty fees$143,19446%
- Travel & lodging$51,33916%
- Food & beverage$6,1812%
- Education$2,4361%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inari Medical, Inc. | 143 | $170,537 |
| Stryker | 22 | $39,511 |
| Johnson & Johnson | 54 | $35,354 |
| Viz.ai, Inc. | 1 | $14,041 |
| Merck | 35 | $13,169 |
| United Therapeutics Corporation | 16 | $9,913 |
| Actelion Pharmaceuticals US, Inc. | 17 | $8,833 |
| Penumbra, Inc. | 3 | $7,276 |
| Cardinal Health 200 LLC | 4 | $6,788 |
| Aidoc Medical Ltd | 2 | $4,750 |
| Nabriva Therapeutics, PLC | 3 | $2,058 |
| Pfizer | 1 | $700 |
| Angiodynamics, Inc. | 3 | $322 |
| Abiomed | 2 | $170 |
| AstraZeneca | 4 | $132 |
| Genentech USA, Inc. | 2 | $119 |
| Insmed, Inc. | 3 | $57 |
| Harmony Biosciences LLC | 1 | $28 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
| Sandoz | 1 | $17 |
| GSK | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CT THROMBECTOMY SYSTEM KIT$208,388
- FLOWTRIEVER CATHETER, S$208,388
- XARELTO$34,697
- Viz.AI LVO$14,041
- WINREVAIR$10,891
- TYVASO$9,517
- UPTRAVI$8,191
- OPSUMIT$8,191
- Indigo System$7,200
- Briefcase$4,750
- Xenleta$2,000
- PAXLOVID$700
- AlphaVac$253
- Impella$144
How this compares
$313,804 in reported general payments places this provider in the 95th percentile of 703 pulmonary disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| WinrevairSotatercept-Csrk | 39 | $688,717 |
| OfevNintedanib Esylate | 28 | $369,926 |
| RemodulinTreprostinil Sodium | 11 | $260,460 |
| NucalaMepolizumab | 47 | $250,548 |
| Dupixent PenDupilumab | 23 | $84,015 |
| Fasenra PenBenralizumab | 15 | $79,512 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 98 | $74,378 |
| TezspireTezepelumab-Ekko | 11 | $40,880 |
| Spiriva RespimatTiotropium Bromide | 40 | $19,619 |
| Breo ElliptaFluticasone/Vilanterol | 49 | $19,327 |
| EliquisApixaban | 24 | $17,209 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 31 | $15,059 |
| Enoxaparin Sodium | 16 | $12,878 |
| Sildenafil Citrate | 50 | $11,959 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 22 | $11,227 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckWinrevair | $13,169 | $688,71739 claims |
| GSKNucala, Trelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $12 | $365,688244 claims |
| United Therapeutics CorporationRemodulin | $9,913 | $260,46011 claims |
| AstraZenecaTezspire, Symbicort | $132 | $44,04625 claims |
| PfizerEliquis | $700 | $17,20924 claims |
| SandozEnoxaparin Sodium | $17 | $12,87816 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 703 pulmonary disease providers in Pennsylvania.
Other pulmonary disease in Philadelphia
- Gerard CrinerPhiladelphia$657K
- Steven GellerPhiladelphia$274K
- Christopher ManleyPhiladelphia$262K
- Jeffrey EdelsonPhiladelphia$233K
- Benjamin WindPhiladelphia$168K
- Boyd HehnPhiladelphia$157K
- Gary AaronsonPhiladelphia$122K
- Friedrich KueppersPhiladelphia$100K
- Philip SilkoffPhiladelphia$88K
- Jeffrey ThompsonPhiladelphia$75K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.